文献速递心血管腹部MR

三尖瓣反流患者的肝脏细胞外容积:一种新的预后标志物

Liver Extracellular Volume in Patients With Tricuspid Regurgitation: A Novel Prognostic Marker.
PubMed 文献 · JACC Cardiovasc Imaging · 2026-10-26

本研究在462例三尖瓣反流患者中评估心脏磁共振测量的肝脏细胞外容积(L-ECV)的预后价值。中位随访2.1年,高L-ECV(≥中位值31%)患者无主要终点生存率更差,且L-ECV独立预测全因死亡和心衰住院(调整HR 1.82,95%CI 1.03-3.18,P=0.030),并在TRI-SCORE基础上提供增量预后价值。

要点

  • L-ECV升高与右心衰临床和影像征象相关,提示系统性静脉淤血。
  • L-ECV可独立于三尖瓣反流严重程度、双心室射血分数和肺动脉压预测预后。
  • L-ECV在TRI-SCORE基础上提供增量预后价值,有助危险分层。

核心结论

  • 在大型真实世界三尖瓣反流队列中,L-ECV是右心衰的新型强力CMR标志物,具有独立和增量预后价值,可对高风险患者进行分层。

研究设计与样本

  • 回顾性队列研究,纳入2019至2024年间因三尖瓣反流转诊并接受CMR参数映射分析的患者462例,中位年龄67岁,43%女性。
  • 主要终点为药物治疗下的全因死亡和心衰住院复合终点,中位随访2.1年。

关键影像表现/征象

  • 高L-ECV(≥中位值31%)患者基线状态更差,有更多右心衰临床和影像征象。
  • 高L-ECV患者无主要终点生存率更低(P < 0.001)。

诊断标准与关键数值

  • L-ECV中位值为31%(Q1-Q3: 28%-35%),以此分组高L-ECV(≥中位值)与低L-ECV。
  • 高L-ECV独立预测主要终点,调整三尖瓣反流严重程度、双心室射血分数和肺动脉压后调整HR为1.82(95% CI: 1.03-3.18; P = 0.030)。
  • L-ECV在嵌套Cox模型中较TRI-SCORE显示增量预后价值。

临床应用与阅片要点

  • 在CMR报告中可考虑量化L-ECV,辅助识别三尖瓣反流患者中右心衰高风险者。
  • L-ECV升高提示系统性静脉淤血,阅片时结合右心衰征象综合评估。
  • L-ECV可补充TRI-SCORE进行危险分层,但需注意本研究为单中心回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Liver extracellular volume (L-ECV), a novel cardiac magnetic resonance (CMR) parameter of systemic venous congestion, might help to stratify tricuspid regurgitation (TR) patients at higher risk, but its role in this context is unexplored.

OBJECTIVES: The aim of this study was to assess the incremental prognostic relevance of L-ECV in a large TR cohort.

METHODS: Data were collected from patients with TR referred to CMR between 2019 and 2024 who had parametric mapping analysis for L-ECV quantification. The primary endpoint was the composite of all-cause mortality and heart failure (HF) hospitalization, under medical management.

RESULTS: In 462 patients included (median age: 67 years; 43% female), median left ventricular ejection fraction was 51% (Q1-Q3: 40%-59%), median tricuspid regurgitant fraction was 21% (Q1-Q3: 14%-33%), and median L-ECV was 31% (Q1-Q3: 28%-35%). When dividing the cohort according to median L-ECV value, patients with high L-ECV (≥ median) showed worse baseline status with more clinical and imaging signs of right HF and (after a median follow-up of 2.1 years) poorer survival free from the primary outcome (P < 0.001) compared with patients with low L-ECV. High L-ECV independently predicted the outcome even after multivariable adjustment accounting for TR severity, biventricular ejection fraction, and pulmonary pressure (adjusted HR: 1.82; 95% CI: 1.03-3.18; P = 0.030). Finally, L-ECV showed incremental prognostic value compared with TRI-SCORE when assessed in a nested Cox model.

CONCLUSIONS: In our large real-world TR cohort, L-ECV appeared as a novel, powerful CMR marker of right HF with an independent and incremental prognostic value to stratify patients with TR at higher risk of events.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Margonato D, Nishihara T, Fukui M, et al. Liver Extracellular Volume in Patients With Tricuspid Regurgitation: A Novel Prognostic Marker. JACC Cardiovasc Imaging. 2026. PMID: 42944652. doi:10.1016/j.jcmg.2026.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。